Immunosuppression Withdrawal

PreclinicalSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Immunosuppression Withdrawal is one of 5 small molecule programs targeting Liver Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantationEnrolling by invitation

Liver TransplantationPreclinical

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Liver Transplantation

#DrugCompanyPhaseTrials

Dolophine

HHikma Pharmaceuticals LLC

Approved

1 2

Ketalar

AAultman Health Foundation

Approved

1 3

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

1 4

Duragesic

CCephalon

Approved

1 5

Immunosuppression Withdrawal

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enrolling by invitation·CChang Gung Memorial Hospital·Preclinical·NCT07735650·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Immunosuppression Withdrawal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunosuppression Withdrawal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunosuppression Withdrawal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Immunosuppression Withdrawal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplant3 trials

Donor1 trial

Liver Transplantation1 trial

References

Drug Info

Quick Facts

Related News